CA3175788A1 - Treatment of acute respiratory distress syndrome and other disorders involving cytokine storm using btk inhibitors - Google Patents

Treatment of acute respiratory distress syndrome and other disorders involving cytokine storm using btk inhibitors Download PDF

Info

Publication number
CA3175788A1
CA3175788A1 CA3175788A CA3175788A CA3175788A1 CA 3175788 A1 CA3175788 A1 CA 3175788A1 CA 3175788 A CA3175788 A CA 3175788A CA 3175788 A CA3175788 A CA 3175788A CA 3175788 A1 CA3175788 A1 CA 3175788A1
Authority
CA
Canada
Prior art keywords
amino
pyrazolo
carbony1
pyrimidin
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3175788A
Other languages
English (en)
French (fr)
Inventor
Claire LANGRISH
Dolca THOMAS
Stefani WOLFF
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Principia Biopharma Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3175788A1 publication Critical patent/CA3175788A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3175788A 2020-04-22 2021-04-21 Treatment of acute respiratory distress syndrome and other disorders involving cytokine storm using btk inhibitors Pending CA3175788A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063013784P 2020-04-22 2020-04-22
US63/013,784 2020-04-22
PCT/US2021/028381 WO2021216696A1 (en) 2020-04-22 2021-04-21 Treatment of acute respiratory distress syndrome and other disorders involving cytokine storm using btk inhibitors

Publications (1)

Publication Number Publication Date
CA3175788A1 true CA3175788A1 (en) 2021-10-28

Family

ID=75919390

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3175788A Pending CA3175788A1 (en) 2020-04-22 2021-04-21 Treatment of acute respiratory distress syndrome and other disorders involving cytokine storm using btk inhibitors

Country Status (12)

Country Link
US (1) US20230158031A1 (enExample)
EP (1) EP4138836A1 (enExample)
JP (2) JP2023522693A (enExample)
KR (1) KR20230015346A (enExample)
CN (1) CN115443136A (enExample)
AU (1) AU2021261327A1 (enExample)
BR (1) BR112022020974A2 (enExample)
CA (1) CA3175788A1 (enExample)
IL (1) IL297316A (enExample)
MX (1) MX2022013164A (enExample)
TW (1) TW202206076A (enExample)
WO (1) WO2021216696A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120617259B (zh) * 2025-06-05 2026-04-10 南昌大学第一附属医院 Btk protac化合物nx-5948的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
PL2710005T3 (pl) * 2011-05-17 2017-07-31 Principia Biopharma Inc. Inhibitory kinazy tyrozynowej
EP2773639B1 (en) * 2011-11-03 2017-04-26 F. Hoffmann-La Roche AG Alkylated piperazine compounds as inhibitors of btk activity
SI2892900T1 (en) 2012-09-10 2018-01-31 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
WO2015095099A1 (en) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Btk inhibitors
WO2015149056A1 (en) * 2014-03-28 2015-10-01 Board Of Regents, The University Of Texas System Inhibition of bruton's tyrosine kinase (btk) in the lung to treat severe lung inflammation and lung injury
WO2016106625A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
WO2021211782A1 (en) * 2020-04-15 2021-10-21 Telios Pharma, Inc. Methods of treating acute lung injury and acute respiratory distress syndrome

Also Published As

Publication number Publication date
BR112022020974A2 (pt) 2022-12-06
AU2021261327A1 (en) 2022-12-22
WO2021216696A1 (en) 2021-10-28
CN115443136A (zh) 2022-12-06
TW202206076A (zh) 2022-02-16
JP2026027386A (ja) 2026-02-18
KR20230015346A (ko) 2023-01-31
IL297316A (en) 2022-12-01
JP2023522693A (ja) 2023-05-31
MX2022013164A (es) 2022-11-30
US20230158031A1 (en) 2023-05-25
EP4138836A1 (en) 2023-03-01

Similar Documents

Publication Publication Date Title
AU2022206693B2 (en) Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
US12473301B2 (en) Isoquinoline compounds for the treatment of cancer
CN117979966A (zh) 使用sos1抑制剂和ras抑制剂治疗癌症
JP2023519890A (ja) 免疫状態の処置のためのｍｋ２経路阻害剤の経口組成物
CN113620958A (zh) 用于治疗PI3K-γ介导的障碍的杂环化合物
D’Cruz et al. Novel Bruton’s tyrosine kinase inhibitors currently in development
JP2017535589A (ja) ２−アミノピリミジン系化合物およびその薬物組成物と使用
JP2026027386A (ja) Ｂｔｋ阻害剤を使用するサイトカインストームを包含する急性呼吸窮迫症候群および他の障害の処置
JP2025134877A (ja) ＢＴＫ阻害剤２－［（３Ｒ）－３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルを使用する、膜性腎症、ＩＧＧ４関連疾患、及び抗リン脂質症候群の処置
EP2729174A1 (en) Il-23 antagonists for treatment or prevention of skin rash associated with treatment with p13k/akt pathway inhibitors
JP2025524002A (ja) 環式化合物及びそれを使用する方法
JP2025526681A (ja) 二環式テトラヒドロチアゼピン誘導体
US20250236614A1 (en) Bicyclic tetrahydroazepine derivatives
HK40122816A (en) Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
HK40049323A (en) Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
JP2023541047A (ja) がんの治療のための複素環式ペリ縮環ｃｄｃ７キナーゼ阻害剤
HK1233180A1 (en) Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
HK1233180B (en) Treatment of b-cell malignancies by a combination jak and pi3k inhibitor

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250415

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250415

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250415

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250422

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250422

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250602

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250602

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250602

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250602

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250605

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260420

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260420